Peter Meldgaard at Aarhus University - Research Interests, Publications & Academic Profile

Peter Meldgaard

Assistant Professor

Aarhus University

Denmark

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Indian students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Cell Biology

40%

Immunology

60%

Oncology

100%

Cancer Biology

80%

Lung Cancer

40%

Cancer Therapy

40%

Tyrosine Kinase

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles17

Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study

Article Link

Year:

2024

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes

Article Link

Year:

2024

Integration of Cell-Free DNA End Motifs and Fragment Lengths Can Identify Active Genes in Liquid Biopsies

Article Link

Year:

2024

Improved overall survival for Stage III NSCLC patients treated with curative-intended therapy from 2010 to 2018–a cohort study in Denmark

Article Link

Year:

2023

Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients.

Article Link

Year:

2023

Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients.

Article Link

Year:

2023

Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor

Article Link

Year:

2023

Can liquid biopsy dynamics stratify patients with small cell lung cancer?

Article Link

Year:

2023

Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB–IIIA Non-Small-Cell Lung Cancer Patients in Denmark

Article Link

Year:

2023

Clinical outcomes of ALK + non-small cell lung cancer in Denmark

Article Link

Year:

2023

TDP1 and TOP1 as targets in anticancer treatment of NSCLC

Article Link

Year:

2022

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.

Article Link

Year:

2022

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study.

Article Link

Year:

2022

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.

Article Link

Year:

2022

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Article Link

Year:

2022

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.

Article Link

Year:

2021

EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP).

Article Link

Year:

2021

Collaborators17

Eric Santoni-Rugiu

Københavns Universitet

DENMARK

Christoffer Trier Månsson

Aarhus University

DENMARK

Ann-Katrine Jakobsen

Aarhus University

DENMARK

Mette Søgaard

Aalborg University

DENMARK

Heidi Søgaard Christensen

Aalborg University

DENMARK

Morten Ladekarl

Aalborg University

DENMARK

Johanne Lade-Keller

Aalborg University

DENMARK

Birgitte Bjørnhart

Odense University Hospital

DENMARK

Boe Sorensen

Aarhus University

DENMARK

Halla Skuladottir

Clinical Associate Professor

Aarhus University

DENMARK

Simone Stensgaard

Aarhus University

DENMARK

Andreas Carus

Aalborg University

DENMARK

Erik Jakobsen

Chief Surgeon

Odense Universitetshospital

DENMARK

Simon Noble

Marie Curie Professor in Supportive and Palliative Medicine

Cardiff University

UNITED KINGDOM

Magnus Stougaard

Aarhus University

DENMARK

Birgitta Ruth Knudsen

Aarhus University

DENMARK

Seppo W. Langer

DENMARK

How do Indian students reach out?

Meet Kite AI

Peter Meldgaard

Assistant Professor

How do Indian students reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles17

Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study

Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes

Integration of Cell-Free DNA End Motifs and Fragment Lengths Can Identify Active Genes in Liquid Biopsies

Improved overall survival for Stage III NSCLC patients treated with curative-intended therapy from 2010 to 2018–a cohort study in Denmark

Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients.

Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients.

Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor

Can liquid biopsy dynamics stratify patients with small cell lung cancer?

Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB–IIIA Non-Small-Cell Lung Cancer Patients in Denmark

Clinical outcomes of <i>ALK</i> + non-small cell lung cancer in Denmark

TDP1 and TOP1 as targets in anticancer treatment of NSCLC

Prognostic value of <i>KRAS</i> mutations, <i>TP53</i> mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study.

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC.

EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP).

Collaborators17

Eric Santoni-Rugiu

Christoffer Trier Månsson

Ann-Katrine Jakobsen

Mette Søgaard

Heidi Søgaard Christensen

Morten Ladekarl

Johanne Lade-Keller

Birgitte Bjørnhart

Boe Sorensen

Halla Skuladottir

Simone Stensgaard

Andreas Carus

Erik Jakobsen

Simon Noble

Magnus Stougaard

Birgitta Ruth Knudsen

Seppo W. Langer

How do Indian students reach out?